Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

PANACEA BIOTEC LTD.

NSE : PANACEABIOBSE : 531349ISIN CODE : INE922B01023Industry : Pharmaceuticals & DrugsHouse : Soshil Kumar Jain

BSE423.7517.05 (+4.19 %)

PREV CLOSE ( ) 406.70

OPEN PRICE ( ) 407.15

BID PRICE (QTY) 423.05 (38)

OFFER PRICE (QTY) 424.30 (31)

VOLUME 23486

TODAY'S LOW / HIGH ( )407.15 432.45

52 WK LOW / HIGH ( )223 581

NSE424.8517.55 (+4.31 %)

PREV CLOSE( ) 407.30

OPEN PRICE ( ) 407.30

BID PRICE (QTY) 424.35 (17)

OFFER PRICE (QTY) 424.75 (5)

VOLUME 254535

TODAY'S LOW / HIGH( ) 407.30 432.40

52 WK LOW / HIGH ( )222.02 581.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984

Management Info

Rajesh Jain - Chairman Rajesh Jain - Managing Director

Registered Office

Address Ambala - Chandigarh Highway,,,
Lalru,
Punjab-140501

Phone 01762- 505900

Email companysec@panaceabiotec.com

Website www.panaceabiotec.com

Registrars Details

Skyline Financial Services Pvt Ltd

D-153/A, 1st Floor,Okhla Industrial Area,Phase - I,New Delhi

Listing : BSE, NSE

NEWS

26May Dividend Announcement
Quarterly Results & Dividend & Audited Results Inter alia, the Board may..

24Apr Panacea Biotec bags additional order f
Panacea Biotec has bagged additional order from United Nations Internati..

24Apr Panacea Biotec touches the roof on bag
Panacea Biotec is locked its upper circuit limit at Rs. 538.90, up by 25..

01Apr Panacea Biotec informs about cessation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

31Jan Panacea Biotec informs about board mee
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosur..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	-67.0000000000001	-152.3
Gross Profit	-88.4	-260.6
Operating Profit	19.3	96.8999999999996
Net Sales	1122.5	3098.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 14203.50 (3.59%)	M.Cap ( in Cr)18143.52
Abbott India (BSE) 32750.00 (1.22%)	M.Cap ( in Cr)68946.55
Astrazeneca Pharma I (BSE) 9081.55 (1.61%)	M.Cap ( in Cr)22648.75
Glenmark Pharma (BSE) 2003.50 (4.42%)	M.Cap ( in Cr)56493.78
Lupin (BSE) 1951.90 (3.33%)	M.Cap ( in Cr)89112.81

Shareholding Pattern

	PROMOTERS	72.48%
	NON-INSTITUTION	25.22%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

PANACEA BIOTEC LTD.